Almirall licenses IL-21 antibody from Novo Nordisk
Pharmaceutical Technology
FEBRUARY 19, 2024
Almirall has signed a licensing agreement for the acquisition of worldwide rights to Novo Nordisk’s IL21-hindering antibody NN-8828.
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Pharmaceutical Technology
FEBRUARY 19, 2024
Almirall has signed a licensing agreement for the acquisition of worldwide rights to Novo Nordisk’s IL21-hindering antibody NN-8828.
Pharmaceutical Technology
MARCH 7, 2024
Gilead Sciences has entered an agreement with Merus for the discovery of dual tumour-associated antigens targeting trispecific antibodies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
MAY 25, 2023
A pair of dual-acting antibodies displayed early potential to become a new type of drug regimen for the blood cancer, but led to a high rate of side effects as well.
Pharmaceutical Technology
MARCH 16, 2023
Talem Therapeutics, a subsidiary of Immunoprecise Antibodies, has entered a multi-target artificial intelligence (AI)-driven antibody discovery collaboration with Libera Bio. The MPN Technology provides an elegant way for delivering antibodies inside tumour cells.
Pharmaceutical Technology
AUGUST 24, 2023
Japan has granted a new drug substance patent for BioArctic’s monoclonal antibody (mAb), BAN0805, to treat Parkinson’s disease.
Pharmaceutical Technology
FEBRUARY 15, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology: Leading companies in cancer monoclonal antibody therapy. Immatics is one of the most important players concerning innovation surrounding cancer monoclonal antibody therapy.
Pharmaceutical Technology
FEBRUARY 22, 2024
The company’s monoclonal antibody therapy, IO-202, has received its second orphan drug designation as a treatment for a blood cancer, CMML.
Pharmaceutical Technology
FEBRUARY 22, 2024
Ono Pharmaceutical has partnered with EME to advance the drug discovery of VHH antibodies to develop new therapeutic agents.
Pharmaceutical Technology
DECEMBER 22, 2023
Ono has signed an agreement with EVQLV to utilise its AI-powered antibody design engine for the development of new antibody drugs.
Pharmaceutical Technology
OCTOBER 21, 2022
AbbVie has announced the acquisition of UK-based biotechnology firm DJS Antibodies for nearly $255m in cash at closing. DJS focuses on the discovery and development of antibody therapies that act on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).
Pharmaceutical Technology
JULY 21, 2022
AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment. In June 2020, these antibodies, discovered at Vanderbilt University Medical Center, were licensed to AstraZeneca.
Drug Discovery World
MARCH 12, 2024
Here, experts weigh in on the future of monoclonal antibodies (mAbs). Amanda Halford, President Bioprocess, Cytiva “In 2024, the emphasis will remain on novel mAbs, specifically antibody drug conjugates. Innovations include next-generation antibodies with improved efficacy and reduced side effects.
Pharmaceutical Technology
FEBRUARY 19, 2024
An FDA approval in late 2024 would make it the first TROP2-directed therapy for NSCLC antibody drug conjugate patients.
Pharmaceutical Technology
JANUARY 9, 2023
Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD). The regulatory approval is based on the data obtained from the Phase II trial.
Pharmaceutical Technology
MAY 8, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-influenza antibody compositions. However, not all innovations are equal and nor do they follow a constant upward trend.
Pharmaceutical Technology
DECEMBER 22, 2023
Discover a groundbreaking method for preparing conditionally active antibodies. This recently granted patent covers evolving DNA to increase acidic amino acid residues, selecting mutants, and assessing activity under specific conditions. Explore the potential of this innovative approach.
Pharmaceutical Technology
JANUARY 23, 2024
Calluna has four monoclonal antibody candidates in the pipeline under development for inflammatory and fibrotic diseases.
Pharmaceutical Technology
MARCH 11, 2024
Discover the groundbreaking trispecific antibody construct patent by Affimed NV targeting CD16A, various antigens, and target cell antigens. Revolutionizing therapy for diseases with lower fratricide levels.
Pharmaceutical Technology
NOVEMBER 28, 2023
Boehringer Ingelheim has entered an agreement with IBM to leverage the latter’s foundation model technologies for antibody discovery.
Pharmaceutical Technology
DECEMBER 11, 2023
Nona Biosciences has entered a partnership deal with biopharmaceutical company Evive Biotech to discover antibodies.
Drug Discovery World
MARCH 4, 2024
In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumour activity in individuals with advanced cancer. The post Antibody therapy shows anti-tumour activity in advanced cancer appeared first on Drug Discovery World (DDW).
Pharmaceutical Technology
DECEMBER 4, 2023
The $247m deal will focus on the use of generative artificial intelligence to develop an antibody therapy for an unnamed cancer.
Pharmaceutical Technology
MAY 24, 2023
HBM’s wholly owned subsidiary Nona Biosciences has entered an agreement with OPKO Health’s ModeX Therapeutics for the discovery of antibodies. ModeX Therapeutics will gain access to the fully human Harbour Mice platforms of Nona Bioscience for integration into its MSTAR platform to expedite the monoclonal antibodies’ discovery.
Drug Discovery World
JANUARY 16, 2024
Biotech company ExeVir Bio has revealed new data demonstrating that its antibodies are effective in neutralising currently circulating Covid-19 Omicron variants. XVR013m is a heavy chain-only antibody targeting a unique membrane-proximal epitope in the S2 subunit of the spike protein. XVR012 demonstrates an IC50 range of 0.8
Pharmaceutical Technology
DECEMBER 21, 2023
The FDA released an updated guidance for developing Covid-19 monoclonal antibody treatments for EUAs as variants evolve.
Pharmaceutical Technology
NOVEMBER 24, 2023
China’s NMPA has approved ArkBio IND application for its respiratory syncytial virus (RSV) neutralising antibody, AK0610.
Pharmaceutical Technology
NOVEMBER 22, 2023
Myricx Bio has signed a licence agreement for contract research, development and manufacturing organisation WuXi Biologics’ antibody.
Bio Pharma Dive
APRIL 21, 2023
A decision by the Supreme Court could have far-reaching effects on the lucrative market for antibody drugs, spurring responses from many of the industry’s top companies.
Pharmaceutical Technology
OCTOBER 12, 2023
Almirall will license EpimAb’s Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to develop up to three bispecific antibody targets.
Pharmaceutical Technology
SEPTEMBER 21, 2023
AbCellera and Regeneron have extended their current multi-target collaboration to discover therapeutic antibodies for up to eight targets
Pharmaceutical Technology
OCTOBER 10, 2023
The companies will develop multiple monoclonal antibodies against membrane proteins, such as GPCRs and SLC transporters.
Pharmaceutical Technology
OCTOBER 17, 2023
LegoChem Biosciences has entered an exclusive worldwide licensing agreement with Glycotope to develop an antibody-drug conjugate (ADC).
Pharmaceutical Technology
OCTOBER 6, 2023
Genomics company Twist Bioscience has entered into an antibody discovery, option and licence agreement with German drug manufacturer Bayer.
Bio Pharma Dive
JUNE 16, 2021
The biotech said it will seek an expanded FDA clearance after results from the RECOVERY trial showed its antibody can lower mortality among certain hospitalized COVID-19 patients.
Drug Discovery World
JANUARY 26, 2024
Researchers from Tokyo University of Science (TUS) have found a simple, low-cost way to optimise the production of monoclonal antibodies (mAbs) and reduce manufacturing costs. We hope that this research will contribute to the stable production of antibody drugs and lead to lower drug prices,” concluded Dr Higashi.
Pharmaceutical Technology
OCTOBER 5, 2023
IMIDomics and WuXi Biologics have signed an agreement to advance the development and manufacturing of the humanised antibody, IMB1001
Drug Discovery World
JANUARY 30, 2024
A UK-based start-up is developing technology to build a pharmaceuticals factory in space that will make antibody treatments more accessible and easier to administer. The post The start-up taking antibodies into space appeared first on Drug Discovery World (DDW).
Pharmaceutical Technology
JULY 4, 2022
Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. The mAb is presently in the Phase II development stage.
Pharmaceutical Technology
SEPTEMBER 14, 2023
AbCellera and Incyte have entered a partnership for the discovery and development of therapeutic antibodies in oncology.
Pharmaceutical Technology
OCTOBER 20, 2023
The company plans to initiate the Phase II trial of anti-IL-6 antibody in atherosclerotic cardiovascular disease in 2024.
Bio Pharma Dive
NOVEMBER 5, 2020
Fast antibody testing, however, is spotty. The drug, now being considered for emergency clearance by the FDA, seems to work best in patients whose immune systems haven't responded to infection.
Drug Discovery World
MARCH 5, 2024
Researchers at the National Institutes of Health have identified antibodies targeting a hard-to-spot region of the influenza virus, shedding light on the relatively unexplored ‘dark side’ of the neuraminidase (NA) protein head.
Bio Pharma Dive
JUNE 18, 2021
drugmaker is the latest to invest large sums of money in antibody-drug conjugates, following recent deals by Gilead, Merck and AstraZeneca.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content